Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials. 

 -  2017 
<br/><br/>Available online from MWHC library: 2000 - after 1 year) 
<br/><br/> CONCLUSIONS: These data suggest that lorcaserin does not adversely affect valvular disease in patients with pre-existing FDA-defined valvulopathy.  Copyright � 2016 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS).  METHODS: This is a pooled, post hoc analysis of three Phase 3 studies. BLOOM and BLOSSOM patients were 18 to 65 years of age without diabetes and with a body mass index (BMI) of 27 to 29.9 kg/m<sup>2</sup> and >1 weight-related comorbidity or a BMI of 30 to 45 kg/m<sup>2</sup> . BLOOM-DM patients had a BMI of 27 to 45 kg/m<sup>2</sup> and type 2 diabetes. Patients were treated with placebo, lorcaserin 10 mg once daily, or lorcaserin 10 mg twice daily. Serial echocardiographs were obtained at baseline and every 6 months.  OBJECTIVE: To evaluate the effects of lorcaserin in patients with pre-existing Food and Drug Administration (FDA)-defined valvulopathy.  RESULTS: Included patients (N = 169) had FDA-defined valvulopathy at baseline and a week 52 echocardiogram. At week 52, 35.5% and 52.7% of patients experienced changes from baseline in aortic and mitral regurgitation, respectively. Numerically greater proportions of patients taking lorcaserin versus placebo had decreases in aortic (33.0% vs. 28.3%) or mitral (41.3% vs. 36.7%) regurgitation. Fewer patients taking lorcaserin versus placebo had increases in aortic (2.8% vs. 6.7%) or mitral (8.3% vs. 21.7%) regurgitation. No adverse event-related discontinuation was due to a valve problem. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1930-7381 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Anti-Obesity Agents/ad [Administration & Dosage]<br/>*Aortic Valve Insufficiency/dt [Drug Therapy]<br/>*Benzazepines/ad [Administration & Dosage]<br/>*Diabetes Mellitus, Type 2/dt [Drug Therapy]<br/>Adult<br/>Aged<br/>Aortic Valve Insufficiency/co [Complications]<br/>Body Mass Index<br/>Body Weight/de [Drug Effects]<br/>Diabetes Mellitus, Type 2/co [Complications]<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Obesity/dt [Drug Therapy]<br/>Randomized Controlled Trials as Topic<br/>Weight Loss/de [Drug Effects]
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article